Hepatocyte growth factor enhances the clearance of a multidrug‐resistant Mycobacterium tuberculosis strain by high doses of conventional chemotherapy, preserving liver function. Issue 2 (8th July 2019)
- Record Type:
- Journal Article
- Title:
- Hepatocyte growth factor enhances the clearance of a multidrug‐resistant Mycobacterium tuberculosis strain by high doses of conventional chemotherapy, preserving liver function. Issue 2 (8th July 2019)
- Main Title:
- Hepatocyte growth factor enhances the clearance of a multidrug‐resistant Mycobacterium tuberculosis strain by high doses of conventional chemotherapy, preserving liver function
- Authors:
- Bello‐Monroy, Oscar
Mata‐Espinosa, Dulce
Enríquez‐Cortina, Cristina
Souza, Verónica
Miranda, Roxana U.
Bucio, Leticia
Barrios‐Payán, Jorge
Marquina‐Castillo, Brenda
Rodríguez‐Ochoa, Ignacio
Rosales, Patricia
Gutiérrez‐Ruiz, María Concepción
Hernández‐Pando, Rogelio
Gomez‐Quiroz, Luis Enrique - Abstract:
- Abstract: Tuberculosis (TB) is one of the deadliest infectious diseases in humankind history. Although, drug sensible TB is slowly decreasing, at present the rise of TB cases produced by multidrug‐resistant (MDR) and extensively drug‐resistant strains is a big challenge. Thus, looking for new therapeutic options against these MDR strains is mandatory. In the present work, we studied, in BALB/c mice infected with MDR strain, the therapeutic effect of supra‐pharmacological doses of the conventional primary antibiotics rifampicin and isoniazid (administrated by gavage or intratracheal routes), in combination with recombinant human hepatocyte growth factor (HGF). This high dose of antibiotics administered for 3 months, overcome the resistant threshold of the MDR strain producing a significant reduction of pulmonary bacillary loads but induced liver damage, which was totally prevented by the administration of HGF. To address the long‐term efficiency of this combined treatment, groups of animals after 1 month of treatment termination were immunosuppressed by glucocorticoid administration and, after 1 month, mice were euthanized, and the bacillary load was determined in lungs. In comparison with animals treated only with a high dose of antibiotics, animals that received the combined treatment showed significantly lower bacterial burdens. Thus, treatment of MDR‐TB with very high doses of primary antibiotics particularly administrated by aerial route can produce a very goodAbstract: Tuberculosis (TB) is one of the deadliest infectious diseases in humankind history. Although, drug sensible TB is slowly decreasing, at present the rise of TB cases produced by multidrug‐resistant (MDR) and extensively drug‐resistant strains is a big challenge. Thus, looking for new therapeutic options against these MDR strains is mandatory. In the present work, we studied, in BALB/c mice infected with MDR strain, the therapeutic effect of supra‐pharmacological doses of the conventional primary antibiotics rifampicin and isoniazid (administrated by gavage or intratracheal routes), in combination with recombinant human hepatocyte growth factor (HGF). This high dose of antibiotics administered for 3 months, overcome the resistant threshold of the MDR strain producing a significant reduction of pulmonary bacillary loads but induced liver damage, which was totally prevented by the administration of HGF. To address the long‐term efficiency of this combined treatment, groups of animals after 1 month of treatment termination were immunosuppressed by glucocorticoid administration and, after 1 month, mice were euthanized, and the bacillary load was determined in lungs. In comparison with animals treated only with a high dose of antibiotics, animals that received the combined treatment showed significantly lower bacterial burdens. Thus, treatment of MDR‐TB with very high doses of primary antibiotics particularly administrated by aerial route can produce a very good therapeutic effect, and its hepatic toxicity can be prevented by the administration of HGF, becoming in a new treatment modality for MDR‐TB. Abstract : HGF protects the liver from anti‐tuberculosis drugs toxicity HGF potentiates the pharmacological effects of anti‐tuberculosis drugs HGF differentially modulates ROS content in the liver and the lungs … (more)
- Is Part Of:
- Journal of cellular physiology. Volume 235:Issue 2(2020:Feb.)
- Journal:
- Journal of cellular physiology
- Issue:
- Volume 235:Issue 2(2020:Feb.)
- Issue Display:
- Volume 235, Issue 2 (2020)
- Year:
- 2020
- Volume:
- 235
- Issue:
- 2
- Issue Sort Value:
- 2020-0235-0002-0000
- Page Start:
- 1637
- Page End:
- 1648
- Publication Date:
- 2019-07-08
- Subjects:
- HGF -- isoniazid -- rifampicin, liver -- tuberculosis
Physiology -- Periodicals
Cell physiology -- Periodicals
571.6 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4652 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jcp.29082 ↗
- Languages:
- English
- ISSNs:
- 0021-9541
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4955.020000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26350.xml